Hyperthermic Intraperitoneal Chemotherapy After Extensive Cytoreductive Surgery in Patients with Primary Advanced Epithelial Ovarian Cancer: Interim Analysis of a Phase II Study
- 327 Downloads
The objective of the current study was to evaluate the toxicities and treatment response of intraoperative hyperthermic intraperitoneal chemotherapy (HIPEC) in patients with advanced epithelial ovarian cancer.
Intraoperative HIPEC (cisplatin 75 mg/m2, 41.5°C, 90 min) was performed in 30 patients with residual tumor of <1 cm after cytoreductive surgery between January 2007 and February 2008. All the patients received adjuvant chemotherapy with combination platinum and taxane. Adverse events and responses to primary treatment were evaluated and scored as follows: grade I, observation; grade II, medical treatment; grade III, intervention; and grade IV, reoperation or admission to the intensive care unit.
No deaths or grade IV morbidities were observed. One hundred seven adverse events were identified in 30 patients (grade I, 40; grade II, 46; grade III, 21). The most common adverse events affected the hematologic system (n = 26), followed by the gastrointestinal system (n = 23). Most adverse events were anemias requiring transfusion and nausea/vomiting requiring medication. Twenty-eight patients (93%) experienced complete remission, and two patients (7%) had progressive disease.
HIPEC after extensive cytoreductive surgery for ovarian cancer is a procedure with acceptable morbidity that patients can tolerate. More follow-up is needed to determine the effect of HIPEC on survival.
- 1.National Cancer Institute. NCI clinical announcement: intraperitoneal chemotherapy for ovarian cancer. 2006. Available at: http://ctep.cancer.gov/highlights/docs/clin_annc_010506.pdf. Accessed January 15, 2009.
- 3.Park S. Postoperative adjuvant intraperitoneal chemotherapy in patients with advanced ovarian cancer. Cancer Res Treat. 2006;38:36s–7s.Google Scholar
- 5.Walker JL, Armstrong DK, Huang HQ, et al. Intraperitoneal catheter outcomes in a phase III trial of intravenous versus intraperitoneal chemotherapy in optimal stage III ovarian and primary peritoneal cancer: a Gynecologic Oncology Group Study. Gynecol Oncol. 2006;100:27–32.PubMedCrossRefGoogle Scholar
- 14.Yan TD, Edwards G, Alderman R, Marquardt CE, Sugarbaker PH. Morbidity and mortality assessment of cytoreductive surgery and perioperative intraperitoneal chemotherapy for diffuse malignant peritoneal mesothelioma—a prospective study of 70 consecutive cases. Ann Surg Oncol. 2007;14:515–25.PubMedCrossRefGoogle Scholar
- 16.Kim S, Kim Y, Kim J. New paradigm of intraperitoneal chemotherapy in ovarian carcinoma. Korean J Gynecol Oncol. 2006;17:1–14.Google Scholar